one-year clinical outcomes of biomatrix™-biolimus a9™ eluting stent: the e-biomatrix multicenter post marketing surveillance registry in india
Clicks: 182
ID: 213919
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
182 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #295 of 437 articles by views in renewable energy
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 437 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective: The e-BioMatrix is a post marketing multicenter registry with an objective to evaluate the 2 year clinical safety and efficacy outcomes in patients treated with BioMatrix™ - Biolimus A9™ (BA9™) drug eluting stents (DES).
Background: Drug-eluting stents still have late-stage disadvantages that might be attributable to the permanent polymer. BioMatrix a new generation DES containing anti-proliferative drug Biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia.
Methods: This interim analysis consists of a total of 1189 patients with 1418 lesions treated with BioMatrix stent who entered this multicenter registry in India. We analyzed the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST) at 1, 6, and 12 months with an extended follow-up of 2 years. Recommended antiplatelet regimen included clopidogrel and aspirin for 12 months.
Results: The mean age was 57.6 ± 10.9 years, 81.8% were males, comorbidity index was 1.20 ± 1.33, 68% presented with acute coronary syndrome, 49% had hypertension and 40.8% had diabetes mellitus. One-year clinical follow-up was completed in 987 patients at the time of interim analysis. The incidence of MACE is 0.45 for 1544 person-year follow-up. There were only 03 cases of ST (01 late ST) reported during this time.
Conclusion: This registry demonstrates excellent one-year clinical safety and efficacy of BioMatrix stents. The 1-year result shows that BioMatrix stent may be a suitable alternative as compared to contemporary DESs which are currently available in the market for simple as well complex disease.
| Reference Key |
mehta2013indianone-year
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ashwin B. Mehta;Praveen Chandra;Jamshed Dalal;Prabhakar Shetty;Devang Desai;K. Chocklingam;Jayesh Prajapati;Pramod Kumar;Vilas Magarkar;Apurva Vasawada;B.K. Goyal;Viveka Kumar;V. Suryaprakash Rao;Ramesh Babu;Pritesh Parikh;Upendra Kaul;Aruna Patil;Tushar Mhetre;Hrishikesh Rangnekar |
| Journal | renewable energy |
| Year | 2013 |
| DOI |
10.1016/j.ihj.2013.08.031
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.